Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes.
Article Details
- CitationCopy to clipboard
Sergerie Y, Boivin G
Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes.
Antiviral Res. 2008 Jan;77(1):77-80. Epub 2007 Sep 17.
- PubMed ID
- 17913252 [ View in PubMed]
- Abstract
Drug-resistant herpes simplex virus type 1 (HSV-1) recombinant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes were evaluated for their susceptibility to various antivirals in the presence of 25 microg/ml of hydroxyurea (HyU). The latter compound decreased the 50% inhibitory concentrations of acyclovir by 1.5-3.8-fold and that of cidofovir by 2.7-14.4-fold. However, HyU did not affect the susceptibilities of the various recombinant mutants to foscarnet. Hydroxyurea, a ribonucleotide reductase inhibitor, can increase the activity of nucleoside/nucleotide analogues against drug-resistant viruses.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Acyclovir DNA polymerase catalytic subunit Protein HHV-1 YesInhibitorDetails Acyclovir DNA polymerase catalytic subunit Protein HHV-3 YesInhibitorDetails Cidofovir DNA polymerase catalytic subunit Protein HHV-5 YesInhibitorDetails